I-Mab Presents Updated Givastomig Data at ESMO 2024
Ticker: NBP · Form: 6-K · Filed: Sep 16, 2024 · CIK: 1778016
Sentiment: neutral
Topics: clinical-data, biotech, conference
TL;DR
I-Mab dropped new cancer drug data at ESMO 2024, check it out.
AI Summary
I-Mab presented updated Phase 1 data for its drug candidate Givastomig at the ESMO 2024 conference on September 16, 2024. The data pertains to the drug's efficacy and safety profile in treating certain cancers.
Why It Matters
This presentation of clinical trial data is crucial for investors and the medical community to assess the potential of Givastomig as a new cancer therapy.
Risk Assessment
Risk Level: medium — Clinical trial data presentations can significantly impact a company's stock price based on the perceived success or failure of the drug candidate.
Key Players & Entities
- I-Mab (company) — Filer of the report and developer of Givastomig
- Givastomig (drug_candidate) — Drug candidate whose data was presented
- ESMO 2024 (conference) — Conference where data was presented
- September 16, 2024 (date) — Date of the press release and data presentation
FAQ
What specific Phase 1 data for Givastomig was presented at ESMO 2024?
The filing states that updated Phase 1 data for Givastomig was presented, but the specific details of this data are not included in this 6-K form, which primarily serves as a cover for the press release.
What is the primary purpose of this 6-K filing?
This 6-K filing is to report a press release regarding I-Mab's presentation of updated Phase 1 Givastomig data at ESMO 2024.
When was the press release attached to this filing issued?
The press release, Exhibit 99.1, is titled 'I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024', and the filing is dated September 16, 2024, indicating the press release was likely issued on or around this date.
What is I-Mab's standard industrial classification?
I-Mab's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Does I-Mab file annual reports under Form 20-F or 40-F?
I-Mab indicates it files annual reports under cover of Form 20-F.
Filing Stats: 154 words · 1 min read · ~1 pages · Grade level 12.9 · Accepted 2024-09-16 16:01:02
Filing Documents
- giva_esmo_data_pr_091620.htm (6-K) — 18KB
- imab-ex99_1.htm (EX-99.1) — 27KB
- 0000950170-24-106805.txt ( ) — 46KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Joseph Skelton Name : Joseph Skelton Title : Chief Financial Officer Date: September 16, 2024